Organogenesis’ (ORGO) “Buy” Rating Reiterated at BTIG Research

BTIG Research reissued their buy rating on shares of Organogenesis (NASDAQ:ORGO) in a research note released on Thursday,Benzinga reports. BTIG Research currently has a $8.00 price objective on the stock.

Other equities analysts have also issued reports about the stock. Wall Street Zen upgraded shares of Organogenesis from a “hold” rating to a “buy” rating in a report on Sunday, March 8th. Weiss Ratings raised shares of Organogenesis from a “sell (d+)” rating to a “hold (c)” rating in a report on Friday, February 27th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.

Organogenesis Price Performance

Shares of ORGO stock opened at $2.29 on Thursday. The firm has a market cap of $294.59 million, a price-to-earnings ratio of 28.63 and a beta of 1.43. Organogenesis has a 12 month low of $2.28 and a 12 month high of $7.08. The company has a quick ratio of 3.32, a current ratio of 3.62 and a debt-to-equity ratio of 0.04. The stock has a 50-day moving average price of $3.36 and a 200 day moving average price of $4.27.

Organogenesis (NASDAQ:ORGO) last released its earnings results on Thursday, February 26th. The company reported $0.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.21 by $0.10. Organogenesis had a net margin of 5.32% and a return on equity of 21.41%. The company had revenue of $225.61 million for the quarter, compared to the consensus estimate of $172.68 million. Research analysts expect that Organogenesis will post -0.07 EPS for the current year.

Insider Activity

In related news, Director Michael Joseph Driscoll bought 10,000 shares of the firm’s stock in a transaction dated Monday, March 9th. The stock was bought at an average cost of $2.67 per share, for a total transaction of $26,700.00. Following the transaction, the director owned 225,707 shares of the company’s stock, valued at $602,637.69. This represents a 4.64% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 33.00% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of ORGO. State of Alaska Department of Revenue bought a new stake in shares of Organogenesis in the 3rd quarter valued at $25,000. Quarry LP acquired a new stake in Organogenesis during the 3rd quarter worth $25,000. Flagship Harbor Advisors LLC bought a new position in Organogenesis during the fourth quarter worth about $34,000. Federated Hermes Inc. lifted its holdings in Organogenesis by 52.8% during the fourth quarter. Federated Hermes Inc. now owns 8,541 shares of the company’s stock worth $44,000 after acquiring an additional 2,953 shares in the last quarter. Finally, Walleye Capital LLC acquired a new position in Organogenesis in the second quarter valued at about $45,000. Institutional investors own 49.57% of the company’s stock.

About Organogenesis

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.